Met Life Investment Management, LLC Aerovate Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.41 - $30.75 $7,371 - $160,761	-5,228 Closed	0 $0
Q1 2024 May 14, 2024	BUY	$17.68 - $29.57 $92,431 - $154,591	5,228 New	5,228 $154,000
Q2 2023 Apr 29, 2024	BUY	$15.63 - $22.01 $81,713 - $115,068	5,228 New	5,228 $89,000
Q1 2023 May 09, 2024	BUY	$19.17 - $27.7 $100,220 - $144,815	5,228 New	5,228 $105 Million
Q4 2022 May 10, 2024	BUY	$15.92 - $30.52 $83,229 - $159,558	5,228 New	5,228 $153,000
Q4 2022 Feb 15, 2023	BUY	$15.92 - $30.52 $83,229 - $159,558	5,228 New	5,228 $153,000

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $65.3M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.